MiNK Therapeutics (INKT) Regains Nasdaq Compliance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. ENOV
4. AON
5. AZN
6. BLSM
7. GRMN
8. GPRO
9. KRMN
10. TXNM

Go back to MiNK Therapeutics (INKT) Regains Nasdaq Compliance

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

February 20, 2025 7:30 AM EST

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, today announced that it has received formal notice from Nasdaq confirming that the Company has regained compliance with both the minimum bid price and market value of listed securities requirements for continued listing on... More